CD274 and neoplasm: Furthermore, this study formed the basis for the FDA approval of clinical testing on tumor tissues to assess PD-L1 expression by SP142 assay to determine the applicability of anti-PDL1 mAb immunotherapy in metastatic TNBC patients [113].